CTXR
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Citius Oncology shipped the first international order of LYMPHIR to EuropeApr 29, 2026
- Citius Oncology reported positive topline results from an investigator-initiated Phase 1 study of LYMPHIR combined with pembrolizumab in relapsed or refractory gynecologic cancersMar 11, 2026
- Citius Oncology expanded European Union distribution of LYMPHIR through an exclusive agreement with UnipharFeb 11, 2026
- Citius Oncology expands LYMPHIR™ distribution to Turkey and Middle East through exclusive agreement with Er-KimDec 4, 2025
- Citius Oncology announced U.S. commercial launch of LYMPHIR™, a novel cancer immunotherapy for cutaneous T-cell lymphomaDec 2, 2025